AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s share price shot up 4.4% during mid-day trading on Monday . The stock traded as high as $0.72 and last traded at $0.71, 1,204,955 shares changed hands during mid-day trading. A decline of 73% from the average session volume of 4,410,685 shares. The stock had previously closed at $0.68.

AVEO has been the topic of several analyst reports. HC Wainwright raised shares of AVEO Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $1.00 to $1.75 in a research note on Wednesday. Piper Jaffray Companies increased their price target on shares of AVEO Pharmaceuticals from $3.00 to $4.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Zacks Investment Research cut shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $2.25.

The business has a fifty day moving average of $0.68 and a 200-day moving average of $0.75. The company has a market cap of $113.57 million, a PE ratio of -5.16 and a beta of 0.74. The company has a current ratio of 2.21, a quick ratio of 2.21 and a debt-to-equity ratio of 6.84.

AVEO Pharmaceuticals (NASDAQ:AVEO) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.04. AVEO Pharmaceuticals had a negative return on equity of 50.69% and a negative net margin of 46.69%. The business had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.78 million. As a group, research analysts predict that AVEO Pharmaceuticals, Inc. will post -0.08 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. NEA Management Company LLC boosted its holdings in AVEO Pharmaceuticals by 20.8% in the second quarter. NEA Management Company LLC now owns 25,243,865 shares of the biopharmaceutical company’s stock valued at $16,913,000 after acquiring an additional 4,347,827 shares in the last quarter. Vanguard Group Inc. increased its position in AVEO Pharmaceuticals by 26.7% during the 2nd quarter. Vanguard Group Inc. now owns 7,670,096 shares of the biopharmaceutical company’s stock valued at $5,164,000 after purchasing an additional 1,614,802 shares during the period. Paloma Partners Management Co purchased a new position in AVEO Pharmaceuticals during the 2nd quarter valued at $321,000. Morgan Stanley raised its holdings in AVEO Pharmaceuticals by 265.4% in the 2nd quarter. Morgan Stanley now owns 399,742 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 290,354 shares in the last quarter. Finally, OZ Management LP bought a new position in AVEO Pharmaceuticals in the 2nd quarter worth $244,000. 29.55% of the stock is owned by institutional investors.

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Article: Dividend Aristocrat Index

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.